Ann: Trading halt, page-419

Gee Stockrock ,..very sensible analysis. We will live another day.

Personally I think we will get an announcement tomorrow and let's get it out the way .. my opinion only .. I'm thinking CLBP.

THEN bring on ARDS .. game changer .. Novartis
Plus in QRT 1 Novartis CHF deal ( you cannot ignore 60% mortality and 60% reduction in MI & Strokes)
Plus in QRT 1 Novartis aGVHD (outside Japan)

On yesterdays call .............did anyone notice, when the Professor made his opening speech (welcoming the investors) .. he said off the bat (before explaining the Dream results ) he would like us (investors) to understand that that MSB has two (2) distinct MSC 's

(1) REMENSTEMCEL-L ( Rynosil / aGVHD / Chrons / ARDS ) ; and

(2) REXLEMESTROCEL L .. worked to reduce 60% mortality & 60% reduction in MI and Strokes ( would have been nice if these were included in pre-specified MACE primary endpoint events. OK they weren't but let BIG Pharma ponder the TRUTH !)

Bottom Line:
I'm not sure why you would make the distinction b/w 1 & 2 above.
.. Covid looking very promising IMO/

Meso .. I'm holding

DYOR and GLTAH.
Anjo